[The use of tranexamic acid during large joint endoprosthetic surgeries]

The aim of the study is to measure the effectiveness and safety of tranexam acid during hip and knee joint endoprothesis surgeries. Tranexam (Mir-Pharm, Russia) was administered to 45 patients 30 minutes before the surgery in the dose of 10-15 mg/kg and 6 hours after first infusion in the same dose. In the control group (n = 45) Tranexam was not administered. The intraoperative, drain and general blood loss, need of donor blood and dynamics of hematological parameters were assessed. The total number of complications and potential transfusion complications was measured. The use of Tranexam acid allowed lowering the blood loss on all the stages of investigation for more than 50%. The general blood loss in the main group was 693.3 +/- 252.2 ml compared to 1259 +/- 454.6 ml in the control group. A need for donor erythrocytes occurred in 2 cases of the main group, who received the total of 3 doses of allogenic blood. In the control group 26 patients received 57 doses of donor blood. There was no need in donor plasma in the main group. The hemoglobin and hematocrit values were higher in the main group compared to the control group. In both cases there were no tromboembolic or transfusional complications. The potential risk of transfusional complications was lower in the main group. Tranexam acid is an effective and safe blood loss prophylaxis measure during the large joint prosthetic surgeries.